AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Clinical trial NCT06511895 · COMPLETED

Trial details

NCT number: NCT06511895
Sponsor: Dizal Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Peripheral T Cell Lymphoma

Start date: 2022-05-31
Primary completion: 2025-10-17
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.